NextCure (NASDAQ:NXTC) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

NextCure (NASDAQ:NXTC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports.

According to Zacks, “NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company’s product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. “

A number of other research analysts have also weighed in on NXTC. Piper Jaffray Companies reissued a “positive” rating and issued a $95.00 target price (up from $54.00) on shares of NextCure in a research note on Monday. Morgan Stanley raised their target price on shares of NextCure from $25.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. Finally, Bank of America raised their target price on shares of NextCure from $27.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, September 9th.

NXTC traded down $0.48 during trading on Tuesday, reaching $38.54. The company’s stock had a trading volume of 14,004 shares, compared to its average volume of 665,824. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.05 and a quick ratio of 17.05. The stock has a fifty day simple moving average of $35.08. NextCure has a 1 year low of $13.86 and a 1 year high of $109.00.

NextCure (NASDAQ:NXTC) last released its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.15). The business had revenue of $1.40 million for the quarter, compared to analyst estimates of $1.50 million. On average, equities analysts anticipate that NextCure will post -1.8 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new stake in shares of NextCure during the 2nd quarter worth approximately $40,611,000. Sofinnova Investments Inc. acquired a new stake in shares of NextCure during the 2nd quarter worth approximately $37,777,000. Citadel Advisors LLC acquired a new stake in shares of NextCure during the 2nd quarter worth approximately $16,385,000. Cormorant Asset Management LP acquired a new stake in shares of NextCure during the 2nd quarter worth approximately $14,980,000. Finally, Hillhouse Capital Management LTD. acquired a new stake in shares of NextCure during the 2nd quarter worth approximately $14,659,000. Institutional investors and hedge funds own 47.19% of the company’s stock.

NextCure Company Profile

There is no company description available for NextCure Inc

Further Reading: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on NextCure (NXTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.